ALX Oncology Announces First Patients Dosed With Evorpacept And Sarclisa As Part Of Randomized Phase 1/2 UMBRELLA Study With Sanofi
Portfolio Pulse from Benzinga Newsdesk
ALX Oncology has dosed the first patients in a Phase 1/2 study of evorpacept combined with Sanofi's SARCLISA for treating relapsed or refractory multiple myeloma. The study aims to overcome resistance to CD38 agents by targeting the CD47 pathway.
September 04, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ALX Oncology has initiated dosing in a clinical study with Sanofi, combining evorpacept with SARCLISA to treat multiple myeloma. This could enhance ALX Oncology's product pipeline and address CD38 resistance.
The initiation of the clinical study with Sanofi is a significant step for ALX Oncology, as it could lead to a new treatment option for multiple myeloma, potentially increasing the company's market value and investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Sanofi is partnering with ALX Oncology in a clinical study to test a combination of SARCLISA and evorpacept for multiple myeloma. This collaboration could enhance Sanofi's oncology portfolio.
Sanofi's collaboration with ALX Oncology in this study could strengthen its position in the oncology market by potentially offering a new treatment for multiple myeloma, thus positively impacting its stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70